Advances in the Management and Prognosis of Brain Metastases
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 433
Special Issue Editors
Interests: brain metastases; non-small cell lung cancer; radiotherapy; chemotherapy
Interests: radiation oncology; brain tumors; brain metastases; tumor microenvironment; cancer therapy; immunotherapy; combination therapy
Special Issue Information
Dear Colleagues,
Brain metastases represent the most common intracranial malignancy, affecting 20–40% of adult cancer patients, with lung, breast, and melanoma accounting for the majority of cases. They carry a poor prognosis, with median survival of only 1–2 months without treatment.
Surgery benefits selected patients with solitary accessible lesions, extending median survival to 10–12 months. Radiotherapy remains a cornerstone: whole-brain radiotherapy achieves disease control but limited survival (3–6 months), whereas stereotactic radiosurgery offers local control rates of 70–90% for limited lesions. Advances in targeted therapy (e.g., EGFR, ALK, HER2 inhibitors) and immunotherapy (checkpoint inhibitors) have improved intracranial response rates (40–70%) and prolonged survival, particularly in lung cancer and melanoma.
Despite these advances, overall survival remains poor. Multidisciplinary care is critical to balancing tumor control, neurologic function, and quality of life. This Special Issue aims to expand our understanding of the latest advances in the management and prognosis of brain metastases, with a particular focus on multimodality approaches.
Dr. Guixiang Liao
Dr. Muhammad Khan
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immunotherapy
- target therapy
- stereotactic radiotherapy
- prognosis
- quality of life
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
